TERT promoter mutations and melanoma survival: A comprehensive literature review and meta-analysis

Crit Rev Oncol Hematol. 2021 Apr:160:103288. doi: 10.1016/j.critrevonc.2021.103288. Epub 2021 Mar 3.

Abstract

We conducted a systematic review and meta-analysis of the association between somatic mutations of the TERT gene promoter and melanoma survival. Data from nineteen independent studies (>2,500 melanoma overall) were pooled using random effects meta-analysis models. TERT-mutated melanoma patients had a significantly worse overall survival (OS) (summary hazard ratio 1.43, 95 % confidence intervals (CI) 1.05-1.95) compared to wild-type ones. The association became stronger when combining risk estimates for overall and melanoma-specific survival (MSS) (1.52, 95 % CI 1.14-2.02), and when restricting the analysis to studies mostly based on invasive non-acral cutaneous melanomas (1.77, 95 % CI 1.00-3.15). Limited, yet suggestive evidence of a detrimental effect of TERT promoter mutations on melanoma prognosis emerged also for other survival measures (e.g. disease-free and distant metastasis-free survival). We found suggestive evidence of a detrimental effect of TERT mutations on melanoma patients' survival.

Keywords: Melanoma; Meta-analysis; Review; Survival; Telomerase reverse transcriptase gene promoter.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Humans
  • Melanoma* / genetics
  • Mutation
  • Prognosis
  • Skin Neoplasms* / genetics
  • Telomerase* / genetics

Substances

  • TERT protein, human
  • Telomerase